Pharmaceutical Technology

MAY 16, 2023

This growth is expected to continue, with a 62% growth in annual consensus sales forecast from 2023 to 2028, fuelled by the company’s semaglutide portfolio, according to GlobalData’s report, ‘Looking ahead to 2023 – the future of pharma’. Novo Nordisk reported an 18.2% million by 2029.

Marketing 52

Marketing Sales Pharma Leads 52

Pharmaceutical Technology

AUGUST 16, 2022

Enhertu has already achieved regulatory approval as a second-line therapy for metastatic or recurrent HER2-positive breast cancer, as well as HER2-positive gastric or gastroesophageal junction adenocarcinoma, with annual sales for these indications alone expected to exceed $1.3bn by 2028.

Food and Drug Administration 59

Food and Drug Administration Sales Patients Food 59

PM360

SEPTEMBER 21, 2023

Generic Drug Launches This year could see up to 50 generic drug approvals on brand pharmaceuticals worth more than $20 billion in sales, Casberg noted. billion in sales. The product had sales of roughly $800 million per year. The drug generated $2 billion in sales last year. “We’re

Management 105

Management Manufacturing Sales Competition 105

Pharmaceutical Technology

DECEMBER 11, 2022

Due to the rarity of the disease, no FDA-approved therapy exists specifically for RT, and these patients are treated using regimens derived from the DLBCL treatment paradigm and other small-scale clinical trials. GlobalData’s consensus analyst forecast database projects peak sales for pirtobrutinib to reach $892 million by 2028, and $4.8

FDA 59

FDA Patients Safety Pharmaceutical 59

European Pharmaceutical Review

MAY 2, 2023

Avacincaptad pegol is forecasted to achieve sales of $1.09 billion in 2028, according to GlobalData’s Pharma Intelligence Center. FDA approves first treatment for geographic atrophy … The post Astellas to accelerate ocular disease treatments with $5.9 billion acquisition appeared first on European Pharmaceutical Review.

Food and Drug Administration 52

Food and Drug Administration Pharma FDA Sales 52

Pharmaceutical Technology

NOVEMBER 8, 2022

Oyster Point Pharma introduced Tyrvaya, a nasal spray approved by the Food and Drug Administration (FDA) to treat dry eye disease, in November last year. These acquisitions could possibly add a minimum of $1bn in sales of Viatris by 2028. These acquisitions could possibly add a minimum of $1bn in sales of Viatris by 2028.

Food and Drug Administration 59

Food and Drug Administration Leads Pharma Food 59

Pharmaceutical Technology

MARCH 30, 2023

In 2022, the company reported Keytuda sales of $20.9 As per GlobalData’s consensus forecasts, the drug is estimated to yield global sales of $34.79 billion in 2028. Earlier in March, the FDA shared a draft guidance on how to run clinical trials for the accelerated approval of cancer drugs. billion in its FY 2022 results.

Food and Drug Administration 52

Food and Drug Administration FDA Sales Food 52

pharmaphorum

OCTOBER 10, 2022

Merck has multibillion-collar sales expectations for sotatercept, which will be at the heart of a renewed push into cardiovascular disease therapies. .” “We are moving with urgency on our regulatory applications to bring this investigational therapy to these patients,” he added.

Sales 52

Sales FDA Pharma Competition 52

Pharmaceutical Technology

MARCH 23, 2023

Among other late-stage trials, Padcev is being evaluated in combination with Keytruda (pembrolizumab) in the frontline setting, with the trial granted priority review by the FDA. This figure derives from net product sales in addition to revenues gained from royalties and licensing agreements.

Engineering 59

Engineering Sales Patients Marketing 59

Pharmaceutical Technology

JULY 12, 2022

The success of chimeric antigen receptor T-cells (CAR-T) in blood cancers has led to the US Food and Drug Administration's (FDA) approval of six products with a pipeline of cell therapies that numbers in the thousands. The total market for cell therapies in oncology is projected to exceed $37bn worldwide by 2028.

Leads 52

Leads Food and Drug Administration Marketing Sales 52

Pharmaceutical Technology

JANUARY 19, 2023

However, it is possible to target CD33 in the clinic, as evidenced by the FDA approval of Pfizer’s anti-CD33 antibody-drug conjugate Mylotarg (gemtuzumab ozogamicin) in 2000. None of these products are in a registrational trial, and as such, GlobalData does not anticipate their entry into the AML market earlier than 2028.

Marketing 52

Marketing FDA Sales Management 52

Clarivate

AUGUST 27, 2024

Since the FDA’s approval of the first pulsed field ablation (PFA) system in the U.S. and ramped up sales of PFA systems in Europe. FDA approval in January 2024. In our September 2023 report on the electrophysiology market, Clarivate projected that by 2028, PFA would represent 50% of the U.S. Boston Scientific Corp.

Marketing 52

Marketing Competition FDA Electronics 52

Contrarian Sales Techniques

FEBRUARY 10, 2023

According to various market research reports, the global non-invasive medical devices market was valued at approximately USD 45 billion in 2020 and is expected to grow at a compound annual growth rate (CAGR) of over 6% from 2021 to 2028. This growth is driven by several factors, including: 1.

Healthcare 52

Healthcare Healthcare Manufacturing Medical 52

Pharmaceutical Technology

OCTOBER 28, 2022

In June 2021, the FDA approved Pfizer’s Prevnar 20 for adult use, although a nod for paediatric use is pending. Merck, known outside of the US and Canada as MSD, is developing its portfolio of pneumococcal vaccines , and has secured an FDA approval for the paediatric use of its 15-serotype vaccine Vaxneuvance in June.

Training 64

Training Marketing Competition FDA 64

pharmaphorum

AUGUST 4, 2022

Ten months after ChemoCentryx scored an unexpected FDA approval for autoimmune disease therapy Tavneos, Amgen has swooped in with a $3.7 billion bid to buy out the company.

Side effects 98

Side effects Sales Pharma Competition 98

Pharmaceutical Technology

APRIL 20, 2023

The district court had previously blocked Sandoz and Zydus from producing, selling, offering to sell, or importing generic versions of Otezla until February 2028. In 2022, Otezla made up for 9% of Amgen’s total product sales, having sold over $2.2 The FDA first approved Otezla in March 2014 for the treatment of psoriatic arthritis.

Competition 52

Competition Marketing FDA Prospecting 52